Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms ( DrugBank: Lansoprazole )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 98 | Eosinophilic gastrointestinal disease | 1 |
98. Eosinophilic gastrointestinal disease
Clinical trials : 171 / Drugs : 184 - (DrugBank : 47) / Drug target genes : 42 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01404832 (ClinicalTrials.gov) | October 2007 | 27/7/2011 | The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors | The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors | Gastroesophageal Reflux Disease;Eosinophilic Esophagitis | Drug: Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms | Dallas VA Medical Center | TAP Pharmaceutical Products Inc. | Terminated | 18 Years | N/A | All | 102 | Phase 4 | United States |